Summary
Eli Lilly & Company (LLY) filed an 8-K on August 8, 2024, to report its financial results for the quarter ended June 30, 2024. The filing primarily consists of a press release, which is furnished as Exhibit 99.1, detailing the company's operational and financial performance for the period. Investors should refer to this press release for specific figures related to revenue, earnings, and other key financial metrics, as well as management's commentary on the results and outlook. This report does not contain new material information beyond the press release itself. Therefore, the most crucial insights for investors will be found within the provided financial results and any forward-looking statements or guidance shared by Eli Lilly in the accompanying press release. It's important to note that the information furnished under Item 2.02 is not considered "filed" for certain regulatory purposes, but it serves as the primary disclosure vehicle for these quarterly results.
Key Highlights
- 1Eli Lilly & Company filed an 8-K on August 8, 2024, reporting Q2 2024 financial results.
- 2The core of the filing is a press release (Exhibit 99.1) containing the detailed financial performance for the quarter ended June 30, 2024.
- 3Investors are directed to the press release for specific revenue, earnings, and operational highlights.
- 4The filing serves as the official disclosure of the company's quarterly financial condition and results of operations.
- 5Information furnished under Item 2.02 is not deemed "filed" for Section 18 of the Exchange Act, but is the standard method for reporting earnings.
- 6The report also includes the Cover Page Interactive Data File.